

SUBJECT INDEX VOLUME 24

A

ACTH, 337, 568
Addiction, 568
Adenosine A₁-receptor, 86
Age effects, 522
Aggression, 37, 370, 502
Alcohol-nonpreferring rats, 691
Alcohol-preferring rats, 691
Allostasis, 97
Alternative splicing, 253
AMPA receptors, 253
Amphetamine, 170, 663
Amygdala, 430, 624
Animal models, 330
Anorexia nervosa, 706
Anpirtoline, 391
Antidepressants, 21, 379, 511, 617
Antipsychotic drug, 278
Anxiety, 31, 161, 430
Apomorphine, 278, 663
Astrocytes, 86
Auditory evoked potential, 671
Autonomic nervous system, 1
Awake, 141

B

Behavior, 1, 691
Behavioral sensitization, 170, 680
Bioethics, 595
Bipolar disorder, 183, 192, 624
Blood-brain barrier, 55
Brain, 291, 652
Bulimia nervosa, 706

C

CA1 pyramidal neuron, 141
CaM kinase, 21
Candidate genes, 467
Caudate nucleus, 47
CB₁ receptor, 198
CB₂ receptor, 198
CCK, 663
CCK-A, 663
Cholecystokinin, 161, 663
Citalopram, 240
Clomipramine, 511
Clozapine, 47, 55, 478
Cocaine, 170, 291, 300, 441, 568, 576
Cocaine abuse, 671
Cognition, 230
Competency, 595
Conditioned place aversion, 152
Conditioned reinforcer, 66
Conditioning, 680
Conflict, 430
Context, 680
Corticosterone, 531
Corticotrophin-releasing hormone (CRH), 531
Corticotrophin-releasing factor (CRF), 1, 624

Cortisol, 37, 278, 590
CP 55, 940, 198
Cytokines, 130

D

Decision making, 595
Delta-9-tetrahydrocannabinol, 198
Dentate gyrus, 608
Depression, 21, 130, 337, 478, 531, 608, 617
Depression model, 632
Depressive disorder, 350
Desipramine, 379, 608
d-Fenfluramine, 492
5,7-Dihydroxytryptamine, 399
Dipeptidyl peptidase IV, 130
Diphosphoinositol polyphosphates, 640
Discrimination learning, 66
Dizocilpine, 663
Docosahexaenoic acid, 55
Dopamine, 55, 319, 561
Dopamine D₃ receptor, 170
Dopamine neurons, 410
Dopamine release, 410
Dopamine transporter, 561
Dopamine type 2 receptor, 553
Dopamine uptake transporter, 553
Dorsal raphe nucleus, 11
Drug addiction, 97
Drug development, 590
Duloxetine, 511

E

Ecstasy, 230, 240
Electrocardiogram, 1
Electrophysiology, 691
Emesis, 198
Emotionality, 337
Endogenous serotonin (5-HT), 141
ERK, 267
Erythrocyte, 192
Estrus cycle, 502
Ethanol consumption, 430
Evoked potential, 230
Extended amygdala, 152
Extinction, 66
Extracellular signal-regulated kinase, 561

F

Fatty acids, 55
Fever, 531
Firing activity, 141
Fluoxetine, 75, 370, 379, 502
Fluoxetine (Prozac), 531
Forced swim test, 391, 632
Forced swimming, 379
Fos, 152
Frontal brain, 337
Frontal cortex, 11, 183

G

GABA, 706
Galanin, 706
Gene expression, 640
Genetics, 291
Genotype, 553
Glutamate, 545
Glycine, 330

H

Habituation, 680
Haloperidol, 170, 240, 663
Heroin, 561
Hippocampus, 183, 330
HPA axis, 568
HPA system, 337
5-HT depletion, 492
5-HT transporter, 652
5-HT_{1A} receptors, 11, 141, 209, 391, 522, 652
5-HT_{1B} receptors, 391
5-HT_{2A} receptors, 319, 652
5-HT_{2C} receptors, 319, 478
5-HTP, 75
Human, 553
6-Hydroxydopamine, 680
5-Hydroxyindoleacetic acid (5-HIAA), 370
5-Hydroxytryptamine uptake, 11
Hypomania, 359

I

Ibotenic acid, 330
Idazoxan, 379
Imipramine, 531
Immobilization stress, 420
Immunocytochemistry, 152
Immunotherapy, 130
Impulsivity, 370
In situ hybridization, 170, 253, 545
Inbred mice, 291
Interactions, 379
Interferon, 130
Interleukin-1 (IL-1), 531
Interleukin-2, 130
Interleukin-6, 86
Intravenous and intracranial self-administration, 300
Ionotropic glutamate receptors, 545
Irritability, 502
Isamoltane, 391

J

JNK, 267

K

Kainic acid, 291
Kappa-opioids, 441

Ketamine, 590
Knock out mice, 576

L

Learning, 680
LETO, 663
Linoleic acid, 55
Lipopolysaccharide (LPS), 531
Lithium, 183, 192, 359, 640
Locomotion, 430
Locomotor activity, 319, 663
LSD, 478

M

Magnetic resonance spectroscopy, 359
Mania, 359
Marijuana, 198
m-Chlorophenylpiperazine, 492
MDMA, 230, 240
Medial frontal cortex, 66
Melatonin, 617
Memantine, 590
Memoriam, 710
Memory, 230
Meta-chlorophenylpiperazine, 31, 37
Methadone, 568
Methamphetamine, 330
3,4-Methylenedioxy-N-methylamphetamine, 240
Metyrapone, 568
Mianserin, 608
Mice, 300
Microdialysis, 11
Milnacipran, 379
Monkey, 230
Mood disorders, 209
Mood stabilizer, 624
Morphine, 75, 576
Mouse, 391
MRI, 47
mRNA differential display, 640
Myristic acid, 55

N

Neurochemistry, 691
Neurokinin A, 183
Neuroprotection, 86
Neuro-receptors, 467
Neurotensin, 170
Neurotoxicity, 492
Nicotine, 350, 576, 671
Nicotinic receptors, 671
Nitric oxide, 420
NMDA, 66, 590
Noradrenaline, 379
Norepinephrine, 617
Novelty, 680
Nucleus accumbens, 253, 410, 576
Nudix hydrolase, 640

O

Obsessive-compulsive disorder, 31
8-OH-DPAT, 379, 399
Oleic acid, 55
OLETF, 663
Open field test, 632
Opiate, 152, 561
Organotypic brain slices, 86
Oxidative stress, 420

P

p38 MAP kinase, 267
Palmitic acid, 55
Panic disorder, 161
Paraphilias, 37
Patient compliance, 192
p-Chlorophenylalanine, 399
Pedophilia, 37
Pentagastrin, 161
Perinatal alcohol, 691
Phencyclidine, 267
Pindolol, 209
Pineal gland, 617
Place conditioning, 75
Place preference, 576
Platelets, 511
Positron emission tomography, 209, 522
Pre-adolescents, 359
Prefrontal cortex, 253, 410, 545
Premenstrual dysphoria, 502
Prepulse inhibition, 399, 663
Primate, 370
Prolactin, 590
Protein phosphorylation, 21
Psychiatric disorders, 595
Psychosis, 671
Psychostimulant drugs, 680
Psychotherapy, 192

R

Randomized clinical trial, 350
Rat, 502, 680
Rat cerebellum, 267
Receptor autoradiography, 545
Recovery, 706
Reinforcement, 300
Resident intruder paradigm, 502
Response inhibition, 66
Reuptake inhibition, 511
Reversal learning, 66
Reward, 66, 300
Reward dysregulation, 97
RNA editing, 478
Rotational behavior, 680
rTMS, 337

S

Schizophrenia, 47, 253, 278, 330, 478, 595, 663

Seizures, 291
Selective serotonin reuptake inhibitors (SSRI), 11
Self-administration, 441
Sensitization, 441
Serotonin (5-HT) release, 492
Serotonin, 31, 37, 75, 240, 319, 370, 379, 399, 430, 467, 478, 502, 561
Serotonin reuptake inhibitor, 502
Signal transduction, 267
Single Photon Emission Tomography, 553
Smoking cessation, 350
SR 141716A, 198
SR 144528, 198
SSRI, 209
Startle, 663
Startle reflex, 399
Strains, 632
Stress, 300, 410, 680
Stress coping, 337
Striatum, 183, 545, 553
Substance P, 183
Suicide, 467, 478
Suicide attempt, 467
Synaptic plasticity, 21
Synaptic vesicle, 21

T

T₃, 632
TMS, 608
Tonic inhibition, 141
Trait anxiety, 300
Treatment outcome, 192
Tricyclic antidepressant, 652
Triiodothyronine, 652
Tumor Necrosis Factor- α (TNF α), 531
Tyramine, 511

U

U69593, 441
Unrestrained, 141

V

Valproic acid, 624
Vasopressin, 161
Ventral tegmental area, 410
Vesicular monoamine transporter, 561
Violence, 37

W

[¹¹C]WAY-100635, 209, 522
WIN 55, 212-2, 198
Withdrawal, 75, 152
Withdrawal symptoms, 350
Working memory, 66